featured
Switching to 6-Week Dosing of Natalizumab vs Continuing With 4-Week Dosing in Patients With Relapsing–Remitting MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Lancet Neurol 2022 Apr 25;[EPub Ahead of Print], JF Foley, G Defer, LZ Ryerson, JA Cohen, DL Arnold, H Butzkueven, G Cutter, G Giovannoni, J Killestein, H Wiendl, K Smirnakis, S Xiao, G Kong, R Kuhelj, N CampbellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.